These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 15905855)
1. Immunotherapy for pancreatic cancer - science driving clinical progress. Laheru D; Jaffee EM Nat Rev Cancer; 2005 Jun; 5(6):459-67. PubMed ID: 15905855 [TBL] [Abstract][Full Text] [Related]
2. Prospects for vaccine therapy for pancreatic cancer. Gaudernack G Best Pract Res Clin Gastroenterol; 2006 Apr; 20(2):299-314. PubMed ID: 16549329 [TBL] [Abstract][Full Text] [Related]
3. Current immunotherapeutic strategies in pancreatic cancer. Plate JM Surg Oncol Clin N Am; 2007 Oct; 16(4):919-43, xi. PubMed ID: 18022552 [TBL] [Abstract][Full Text] [Related]
4. New frontiers in cell-based immunotherapy of cancer. D'Elios MM; Del Prete G; Amedei A Expert Opin Ther Pat; 2009 May; 19(5):623-41. PubMed ID: 19441938 [TBL] [Abstract][Full Text] [Related]
5. [Oncoimmunology: some fundamental problems of cancer immunotherapy]. Nedospasov SA; Kuprash DV Mol Biol (Mosk); 2007; 41(2):355-68. PubMed ID: 17514902 [TBL] [Abstract][Full Text] [Related]
6. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Lynch DH Immunol Rev; 2008 Apr; 222():277-86. PubMed ID: 18364008 [TBL] [Abstract][Full Text] [Related]
11. Tumor-associated antigens and biomarkers in cancer and immune therapy. Malyankar UM Int Rev Immunol; 2007; 26(3-4):223-47. PubMed ID: 17558745 [TBL] [Abstract][Full Text] [Related]
12. [Immunotherapy for cancer--modern immunologic strategies in oncology]. Halama N; Zoernig I; Jäger D Dtsch Med Wochenschr; 2008 Oct; 133(41):2105-8. PubMed ID: 18985564 [TBL] [Abstract][Full Text] [Related]
13. Advances in specific immunotherapy for prostate cancer. Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335 [TBL] [Abstract][Full Text] [Related]
15. Potential target antigens for immunotherapy in human pancreatic cancer. Schmitz-Winnenthal FH; Galindo-Escobedo LV; Rimoldi D; Geng W; Romero P; Koch M; Weitz J; Krempien R; Niethammer AG; Beckhove P; Buchler MW; Z'graggen K Cancer Lett; 2007 Jul; 252(2):290-8. PubMed ID: 17320278 [TBL] [Abstract][Full Text] [Related]
16. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. Gray A; Raff AB; Chiriva-Internati M; Chen SY; Kast WM Immunol Rev; 2008 Apr; 222():316-27. PubMed ID: 18364011 [TBL] [Abstract][Full Text] [Related]
17. Q&A: Evidence presenter. Interview by Marian Turner. Palucka K Nature; 2013 Dec; 504(7480):S9. PubMed ID: 24352364 [No Abstract] [Full Text] [Related]
18. Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy. Sigalotti L; Coral S; Fratta E; Lamaj E; Danielli R; Di Giacomo AM; Altomonte M; Maio M Semin Oncol; 2005 Oct; 32(5):473-8. PubMed ID: 16210088 [TBL] [Abstract][Full Text] [Related]